Pharma to Meet Biotech at the European Business Development Conference in July in Hamburg

In a couple of weeks, representatives of the European biotechnology sector will meet  experts from the international pharmaceutical industry for the fifth time at the European Business Development Conference in Hamburg. On 20 and 21 July, around 100 participants will discuss a variety of aspects concerning the topic of “Pharma Biotech Cooperation – Driving Health Business”, at the Empire Riverside Hotel on Landungsbrücken in the harbour city. Andreas Busch, a member of the executive committee of Bayer Healthcare Pharmaceuticals, and Franz-Robert Klingan of Bain & Company will be this year’s keynote speakers.

In addition, representatives of companies including Affiris, Burril & Co., Celgene, Daiichi-Sankyo, Fresenius Biotech, Forbion Capital Partners, GSK, Index Ventures, Menarini, Merck-Serono, Pfizer, Sanofi and Wilex are expected.

The topics of research and development alliances, therapeutic vaccines, alternatives to private equity, and the prospects for personalised medicine as a business model for pharma and biotech will be debated during panel discussions and plenary sessions.

Participants will have the opportunity to acquire an insight into the latest research and development activities by European biotechnology companies during the up to 16 company presentations to the entire assembly.

Once again this year, the conference will provide a chance for stimulating discussions during frequent breaks in the stylish atmosphere of the hotel, which was designed by the renowned architect David Chipperfield. In the evening, there will be a dinner for guests on a boat in the Hamburg harbour – what else would one expect in this metropolis on the Elbe? The club facilities of the historical tall ship, Rickmer Rickmers, which is now permanently moored as a museum ship in Hamburg, will provide the setting for the participants to conclude the first day of the conference biotechnology.

The event is supported by a large number of international organisations. The European Association of Pharma Biotechnology (EAPB) is this year’s European partner. In addition, several national biotechnology associations from Europe and North America, as well as biotechnology  lobby groups, are supporting the conference: ASEBIO – Asociación Española de Bioempresas (Spain), ASSOBIOTEC – Associazione Italiana per lo Sviluppo delle Biotecnologie and Biotech-in-Italy (Italy), BIA - Bioindustry Organisation (Great Britain), BIOTECanada (Canada), Lisa – Life Science in Austria (Austria), swedenBIO – The Sweden Life Science Organisation (Sweden), and the Swiss Biotech Association (Switzerland).

Norgenta GmbH, the life-science initiative of the federal states of Hamburg and Schleswig-Holstein, is this year’s platinum sponsor. Merck-Serono is the gold sponsor, while Bayer und the Mig Fund are the silver sponsors. Amantec, Daiichi-Sankyo, Life Science Consult, Menarini Biotech, Parexel, Pfizer and Rentschler Biotechnologie are this year’s official conference supporters.

For further information and registration, please see:

www.biodeutschland.org/business-development-conference-2011-hamburg-germany.html